Tech News Summary:
- AstraZeneca has launched Evinova, a new global health technology business, to improve the efficiency of clinical trials and the experience for patients involved in these trials.
- Evinova, financially backed by AstraZeneca but operating as a separate entity, will focus on designing, executing, and monitoring clinical trials, aiming to streamline and simplify the process.
- The revenue-based model of Evinova represents a unique approach to offering and paying for clinical trial services, reflecting AstraZeneca’s positioning at the forefront of innovation within the industry.
AstraZeneca, one of the world’s leading pharmaceutical companies, has announced its entry into the health tech industry with the unveiling of Evinova, a new clinical services business. The move marks a significant expansion of the company’s offerings beyond traditional drug development and into the rapidly growing healthcare technology sector.
Evinova will focus on providing a range of clinical services, leveraging AstraZeneca’s deep expertise in drug development and clinical research. The new business unit aims to address the growing need for digital health solutions and services, particularly in the areas of patient recruitment, real-world evidence generation, and remote patient monitoring.
According to AstraZeneca, Evinova will bring together the company’s existing capabilities in clinical research, data science, and digital health to provide innovative solutions to healthcare providers, payers, and patients. The new business is poised to leverage the power of big data and advanced analytics to improve clinical trial efficiency, patient outcomes, and overall healthcare delivery.
Pascal Soriot, CEO of AstraZeneca, commented on the launch of Evinova, stating, “We are excited to enter the health tech space with the introduction of Evinova. This move underscores our commitment to innovation and our belief in the potential of digital health to transform patient care. We believe that Evinova has the potential to be a game-changer in the healthcare industry, offering a range of cutting-edge clinical services that will bring significant value to patients and healthcare stakeholders.”
The announcement comes at a time of rapid growth and investment in the health tech sector, with the COVID-19 pandemic driving increased demand for digital health solutions and services. AstraZeneca’s entry into this space is expected to further fuel innovation and competition in the industry, ultimately benefiting patients and healthcare systems worldwide.
Overall, the unveiling of Evinova represents a significant strategic move for AstraZeneca as it continues to diversify its business and establish a presence in the global health tech market. With its extensive resources and expertise in drug development, the company is well-positioned to make a meaningful impact in this burgeoning sector.